Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
:CVKD
CVKD Stock Chart & Stats
$12.92
-$1.27(-7.12%)
At close: 4:00 PM EST
$12.92
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$8.74 - $22.90
Previous CloseN/A
Volume16.20K
Average Volume (3M)24.84K
Market Cap
$24.97M
Enterprise ValueN/A
Total Cash (Recent Filing)$5.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 06, 2025EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding2,046,854
10 Day Avg. Volume23,604
30 Day Avg. Volume24,840
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.38
Price to Sales (P/S)0.00
P/FCF Ratio-2.40
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$45.00Price Target Upside248.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-7.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThis is seen as a significant development for Cadrenal that advances a second tecarfarin indication to clinical trials.
Efficacy And Patient OutcomesTecarfarin has shown improvements in efficacy and the ability to maintain the patient within their target blood clotting ranges, potentially reducing hospitalization rates, morbidity, and mortality.
PartnershipsCadrenal announced a development agreement with Abbott to develop Tecarfarin in patients with Abbott’s HeartMate3 LVAD.
Bears Say
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $8.74 and its highest was $22.90 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $24.97M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is 3 days ago.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Aug 11, 2025. The company reported -$1.87 earnings per share for the quarter, missing the consensus estimate of -$1.775 by -$0.095.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,046,854 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.87 in its last earnings report, missing expectations of -$1.775. Following the earnings report the stock price went down -4.314%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. (CVKD) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of cardiovascular diseases. The company is dedicated to addressing unmet medical needs by advancing innovative solutions that improve patient outcomes. Its core product offerings typically revolve around proprietary drug formulations and therapeutic interventions aimed at treating specific cardiac-related conditions.
CVKD Stock 12 Month Forecast
Average Price Target
$45.00
▲(248.30% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
52.61% Insiders
2.95% Mutual Funds
<0.01% Other Institutional Investors
42.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---